<div id="readability-page-1"><p>3Chopt Investment Partners LLC cut its position in  Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 57.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,460 shares of the biopharmaceutical company's stock after selling 36,326 shares during the quarter. 3Chopt Investment Partners LLC's holdings in Bristol Myers Squibb were worth $1,193,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. New England Asset Management Inc. boosted its holdings in  Bristol Myers Squibb by 0.8% during the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock valued at $2,408,000 after acquiring an additional 305 shares during the period.  Commonwealth Retirement Investments LLC increased its stake in  Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company's stock worth $2,740,000 after purchasing an additional 11,690 shares during the period.  Norges Bank bought a new stake in shares of  Bristol Myers Squibb during the second quarter worth $1,554,154,000.  Wealth Quarterback LLC boosted its stake in shares of  Bristol Myers Squibb by 42.6% during the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company's stock valued at $1,178,000 after purchasing an additional 7,603 shares during the period.  Finally, Sound View Wealth Advisors Group LLC grew its holdings in shares of  Bristol Myers Squibb by 438.0% in the second quarter. Sound View Wealth Advisors Group LLC now owns 307,849 shares of the biopharmaceutical company's stock worth $14,250,000 after purchasing an additional 250,624 shares during the last quarter. Institutional investors own  76.41% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>Several equities research analysts have issued reports on BMY shares. The Goldman Sachs Group  reissued a &#34;neutral&#34; rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. HSBC  reiterated a &#34;hold&#34; rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Morgan Stanley  restated an &#34;underweight&#34; rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Guggenheim  reiterated a &#34;buy&#34; rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Finally, Sanford C. Bernstein  reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Six investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one  has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $54.62.</p><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p><b>Read Our Latest Analysis on Bristol Myers Squibb</b></p><h2>Bristol Myers Squibb Stock Up 0.2%</h2><p>NYSE:BMY opened at $54.22 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a market cap of $110.38 billion, a PE ratio of 18.32, a P/E/G ratio of 8.28 and a beta of 0.29. The company's 50 day moving average is $49.23 and its two-hundred day moving average is $47.39. </p><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter in the previous year, the business earned $1.80 EPS. The company's quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.  Analysts anticipate that  Bristol Myers Squibb Company will post 6.74 EPS for the current year. </p><h2>Bristol Myers Squibb Increases Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This is an increase from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 83.78%. </p><h2>Bristol Myers Squibb Profile</h2> (Free Report)<p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.  </p><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p><h2>Read More</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>Do not delete, read immediately</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>[No Brainer Gold Play]: “Show me a better investment.”</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>3Chopt Investment Partners LLC reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 57.9% in Q3, selling 36,326 shares and holding 26,460 shares valued at $1.19 million. Other institutional investors also adjusted their positions, with significant increases from New England Asset Management and Commonwealth Retirement Investments. Analysts have mixed ratings on BMY, with an average target price of $54.62. The stock opened at $54.22, showing a slight increase of 0.2%. Bristol Myers Squibb reported strong quarterly earnings, exceeding estimates with $1.63 EPS and $12.22 billion in revenue.</p>

3Chopt Investment Partners LLC Sells 36,326 Shares of Bristol Myers Squibb Company $BMY